Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580799 | 0.82 | GRM2 (0.38) | JAK1JAK3 | |
| SCHEMBL14252157 | 0.81 | BRD4 (0.45) | HSP90AA1HSP90AB1BRD4 | |
| SCHEMBL12819928 | 0.72 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1JAK1JAK3HSP90B1 | |
| SCHEMBL4582034 | 0.72 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1JAK1JAK3HSP90B1 | |
| SCHEMBL12191238 | 0.71 | JAK2 (0.52) | HSP90AA1HSP90AB1JAK1JAK3HSP90B1 | |
| SCHEMBL1220618 | 0.70 | KDM4E (0.51) | HSP90AA1HSP90AB1JAK1JAK3 | |
| SCHEMBL2427377 | 0.70 | CREBBP (0.51) | HSP90AA1HSP90AB1JAK1JAK3 | |
| SCHEMBL30853881 | 0.69 | BRD4 (0.52) | BRD4 | |
| SCHEMBL1747367 | 0.69 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820674 | 0.68 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | claimed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024961-A1 | DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024961-A1 | DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | QDPR, CCND2, CCND1 | HSP90AA1 2362/4885HSP90AB1 2403/4885BRD4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.